Gene Editing Enables Immune System to Produce Therapeutic Proteins

Recent advances in genetic engineering have opened a promising new frontier in medicine: programming the body’s own immune system to manufacture therapeutic proteins internally. This approach, which combines gene editing technologies like CRISPR with cellular immunotherapy, aims to transform patients’ B cells or T cells into living factories that produce antibodies, cytokines, or other biologics exactly where and when they are needed. By eliminating the need for frequent external drug administration, this strategy could improve treatment adherence, reduce side effects, and lower healthcare costs for chronic conditions ranging from autoimmune diseases to cancer and genetic disorders.

Researchers are now demonstrating proof-of-concept in preclinical models, showing that edited immune cells can secrete functional proteins in response to physiological cues, offering a dynamic and self-regulating alternative to traditional biologic therapies.

How Immune Cells Are Reprogrammed to Make Therapeutic Proteins

The core idea behind this innovation is to harness the natural protein-producing machinery of immune cells — particularly B lymphocytes, which evolved to generate vast quantities of antibodies — and redirect it toward therapeutic ends. Using gene editing tools, scientists insert DNA sequences encoding desired proteins (such as neutralizing antibodies, insulin, or clotting factors) into the genome of immune cells, often under the control of promoters that activate in response to specific stimuli like inflammation or antigen exposure.

In one approach, researchers extract a patient’s T cells or B cells, edit them ex vivo using viral vectors or electroporation to deliver CRISPR components, and then reinfuse the modified cells back into the body. Once inside, these cells engraft, proliferate, and begin producing the encoded protein. Unlike conventional gene therapy that targets liver or muscle cells, this method leverages the immune system’s natural ability to expand, surveil tissues, and respond to disease signals — providing built-in regulation and localization.

Alternative strategies involve in vivo delivery of gene-editing machinery via lipid nanoparticles or engineered viral vectors designed to target immune cells directly within the body, avoiding the need for cell extraction and manipulation outside the body.

Recent Advances and Preclinical Successes

In 2023, a team at the University of Pennsylvania demonstrated that CRISPR-edited B cells could be programmed to secrete broadly neutralizing antibodies against HIV, providing sustained protection in animal models. The edited cells persisted for months and adjusted antibody output in response to viral exposure, mimicking the adaptive nature of natural immunity.

Similarly, researchers at Memorial Sloan Kettering Cancer Center have engineered T cells to produce interleukin-12 (IL-12), a potent antitumor cytokine, only upon encountering cancer-specific antigens. This localized delivery minimizes the systemic toxicity typically associated with cytokine therapies while enhancing antitumor activity.

Another breakthrough came from scientists at Boston Children’s Hospital, who used base editing to correct a mutation in the Factor IX gene in hemophilia B model mice. By editing hepatic B-cell precursors, they achieved long-term expression of functional clotting factor, reducing bleeding episodes without the need for regular factor infusions.

These studies highlight the versatility of the approach: whether the goal is to replace a missing protein, modulate immune activity, or directly attack diseased cells, the immune system can be tailored to serve as a drug delivery system.

Advantages Over Conventional Biologic Therapies

Traditional biologic drugs — such as monoclonal antibodies, enzyme replacements, or cytokine therapies — require repeated intravenous or subcutaneous injections, often weekly or biweekly. This regimen poses challenges for patient compliance, especially in chronic diseases. Manufacturing and storage costs are also high, and some patients develop anti-drug antibodies that neutralize the therapy over time.

In contrast, immune cell-based protein production offers several potential benefits:

• Sustained, localized delivery: Edited cells can reside in tissues for years, providing continuous therapeutic protein production where it’s needed most.
• Reduced dosing frequency: A single treatment could offer months or years of benefit, decreasing the burden on patients and healthcare systems.
• Personalized responsiveness: By linking protein output to disease-specific triggers (e.g., tumor antigens or inflammatory signals), therapy can self-adjust in real time.
• Lower immunogenicity risk: Using the patient’s own cells minimizes the chance of immune rejection compared to foreign protein therapeutics.

Challenges and Safety Considerations

Despite its promise, this technology faces significant hurdles before widespread clinical use. Key concerns include:

• Off-target editing: CRISPR systems may inadvertently alter unintended parts of the genome, potentially causing mutations that lead to cancer or other disorders.
• Insertional mutagenesis: Viral vectors used to deliver genetic material can disrupt tumor suppressor genes or activate oncogenes if integration occurs in risky genomic regions.
• Immune reactions to edited cells: Although autologous cells reduce rejection risk, the introduction of foreign genetic material or non-human protein sequences could still provoke immune responses.
• Long-term persistence and control: Ensuring that edited cells do not overproduce therapeutic proteins or persist uncontrollably requires sophisticated safety switches, such as inducible promoters or suicide genes.

To address these risks, researchers are refining gene-editing precision through improved CRISPR variants (like base and prime editing), developing non-integrating delivery methods, and incorporating rigorous safety controls into cellular designs.

Current Clinical Trials and Future Outlook

As of 2024, several early-phase clinical trials are underway evaluating edited immune cells for therapeutic protein production. Notable examples include:

• A trial by CRISPR Therapeutics and Vertex Pharmaceuticals investigating CTX001 (ex vivo edited hematopoietic stem cells) for sickle cell disease and beta-thalassemia — while not focused on immune cells, it establishes safety and efficacy foundations for in vivo editing.
• Studies by Allogene and Caribou Biosciences exploring allogeneic edited T cells for cancer that secrete cytokines or checkpoint modulators.
• Preclinical programs by companies like Scribe Therapeutics and Beam Therapeutics aiming to edit B cells in vivo for antibody secretion against infectious diseases and autoimmune targets.

Experts anticipate the first approvals for immune cell–based protein therapies could emerge within the next five to seven years, initially targeting rare genetic disorders or refractory cancers where current options are limited.

The convergence of synthetic biology, immunology, and gene editing is shifting the paradigm from administering drugs to engineering the body to make them. If safety and long-term efficacy can be established, this approach may one day transform how we treat a wide range of diseases — turning patients into their own pharmaceutical factories.

Frequently Asked Questions